Clinical Trial Update: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]

View source ↗

Summary

This Clinical Trial Update describes a Phase 1 study evaluating CAR-GPRC5D cell therapy in patients with relapsed/refractory multiple myeloma or plasma cell leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• CAR-GPRC5D

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Status: RECRUITING